QCM
BCRX icon

Quantinno Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Quantinno Capital Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
137,453
+57,392
+72% +$519K ﹤0.01% 2302
2026
Q1 		$762K Buy
80,061
+56,909
+246% +$442K ﹤0.01% 2391
2025
Q4 		$181K Sell
23,152
-6,369
-22% -$46K ﹤0.01% 3069
2025
Q3 		$224K Buy
29,521
+10,375
+54% +$86.4K ﹤0.01% 2689
2025
Q2 		$172K Buy
19,146
+2,286
+14% +$21.3K ﹤0.01% 2402
2025
Q1 		$126K Buy
16,860
+2,032
+14% +$16.4K ﹤0.01% 1979
2024
Q4 		$112K Buy
14,828
+4,097
+38% +$31.1K ﹤0.01% 1603
2024
Q3 		$81.6K Buy
+10,731
New +$81.6K ﹤0.01% 1447

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Quantinno Capital Management's BCRX Position: Q2 2026 in Review

Quantinno Capital Management increased its BioCryst Pharmaceuticals (BCRX) stake by 72% in Q2 2026, buying an estimated $519K and bringing the position to 137,453 shares worth $1.37M. The position accounts for ﹤0.01% of the portfolio, ranked #2302.

Quantinno Capital Management first reported a position in BCRX in Q3 2024 and has held it in 8 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Quantinno Capital Management held 137,453 shares of BioCryst Pharmaceuticals worth $1.37M as of Q2 2026.
  • Quantinno Capital Management bought 57,392 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $519K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Quantinno Capital Management's portfolio in Q2 2026, its #2302 holding.
  • Quantinno Capital Management first reported a position in BioCryst Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Quantinno Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.